Background and Aim: Previous studies have suggested that chronic pancreatitis (CP) is associated with increased risk of cardiovascular (CV) disease independently of other major risk factors. We evaluated the risk of CV events in a well-phenotyped cohort of patients with CP and its association with pancreatic exocrine insufficiency (PEI) among other CV risk factors. Methods: This was a prospective, longitudinal cohort study of patients with CP, followed up at the Pancreas Unit of the University Hospital of Santiago de Compostela, Spain. Results: Four hundred thirty patients were included (mean 47.8 ± 14.4 years of age, 79.1% male). Mean follow-up was 8.6 ± 4.6 years. CP etiology was toxic (alcohol and/or smoking) in 290 patients (67.4%). PEI and pancreatogenic diabetes mellitus (DM) were present in 29.3% and 29.5% of the patients, respectively. A total of 45 CV events was recorded (10.5%); 21 patients had a major CV event (stroke or myocardial infarction) and 27 developed clinically relevant peripheral arterial disease. A higher incidence of CV events was recorded in patients with PEI than in those without (incidence rate ratio 3.67, 95% confidence interval [CI] 1.92-7.24; P < 0.001). In the multivariate analysis, PEI without DM (OR 4.96; 95% CI 1.68 to 14.65), coexistence of PEI and DM (OR 6.54; 95% CI 2.71 to 15.77), arterial hypertension (OR 3.40; 95% CI 1.50 to 7.72), and smoking (OR 2.91, 95% CI 1.07 to 7.97) were independently associated with increased CV risk. Conclusions: Together with known major CV risk factors like smoking and hypertension, PEI is significantly associated with the risk of CV events in patients with CP.
Introduction
Chronic pancreatitis (CP) is a debilitating condition associated with substantial morbidity and mortality. 1, 2 Prolonged inflammation results in destruction of healthy pancreatic parenchyma and development of tissue fibrosis. 3 This causes irreversible loss of exocrine function, which manifests as impaired production and secretion of digestive enzymes in response to ingested nutrients, 4 as well as permanent loss of endocrine function. Common secondary consequences of CP include therefore pancreatic exocrine insufficiency (PEI) and pancreatogenic diabetes mellitus (DM). 1, 2, 5, 6 PEI leads to maldigestion, with resultant malabsorption of fat, protein, and fat-soluble vitamins, leading ultimately to nutritional deficiencies. 7, 8 Approximately 35-50% of patients with CP are believed to develop PEI within 10-15 years of disease onset 2 and require pancreatic enzyme replacement therapy (PERT) to restore a normal nutritional status. 5, 9 There is evidence that CP is associated with an increased risk of cardiovascular (CV) disease, 10, 11 which may be explained, at least partially, because they share many risk factors (e.g. smoking and DM). Nutritional deficiencies have been also associated with CV disease and CV events, [12] [13] [14] [15] [16] [17] but the role of PEI as a predisposing cause of CV events is unknown. In a recent study evaluating the etiology, pathogenesis, and natural history of CP (EPNAT-CP study), we showed that PEI is significantly associated with increased mortality in patients with CP. 18 We hypothesized that PEI, as a cause of nutritional deficiencies, may be associated with an increased risk of CV events in the same population.
Study objective. The aim of this study was to evaluate the impact of PEI on the risk of CV events in patients with CP.
Materials and methods
Study design. This was a prospective, longitudinal cohort study of well-phenotyped patients with CP who had previously participated in a large prospective, single-center cohort study on the EPNAT-CP, between 2005 and 2015 (PI10/01983), and who remain under standardized long-term follow-up at the Pancreas Unit of the University Hospital of Santiago de Compostela, Spain. The study aimed to further examine the interaction between different CP etiologies and disease prognosis. This patient cohort has been described in detail elsewhere. 18 Patient inclusion criteria. In short, patients diagnosed with CP based on symptoms and generally accepted criteria of the disease on endoscopic ultrasound (EUS), computed tomography scan, magnetic resonance imaging, magnetic resonance pancreatography after intravenous secretin, and secretinstimulated pancreatic secretion of bicarbonate at the endoscopic pancreatic function test [19] [20] [21] [22] [23] [24] [25] were included. All included patients had an increased strain ratio on pancreatic EUS elastography, indicating the presence of pancreatic fibrosis. 26 Patients were excluded if they refused to participate in the study or if they were lost to follow-up, or followed up at another center.
Study assessments. At inclusion, a comprehensive interview and clinical evaluation including demographics, toxic habits, symptoms, physical examination, hemogram and standard serum parameters, nutritional evaluation, morphological and functional pancreatic evaluation, etiological evaluation according to the TIGAR-O classification, 27 and comorbidities were conducted. Pancreatic function was evaluated by the 13 C-labeled mixed triglyceride ( 13 C-MTG) breath test, as described previously. 28 DM was classified as present if subjects had a fasting plasma glucose level ≥ 126 mg/dL and/or a hemoglobin A1c (HbA1C) ≥ 6.5%, or being under antidiabetic therapy at inclusion. Hypercholesterolemia was defined as fasting plasma cholesterol > 220 mg/dL, low density lipoprotein > 130 mg/dL, or being under lipid-lowering drugs at inclusion. Arterial hypertension was defined as a systolic blood pressure ≥ 140 mmHg, a diastolic blood pressure ≥ 90 mmHg, or being under antihypertensive treatment at inclusion.
Smoking was defined as a lifetime consumption of ≥ 100 cigarettes. Number of cigarettes per day and years of habit were recorded. Smokers were classified as current (those who smoked either every day or some days) and former smokers (those who did not smoke) at the baseline inclusion visit. A comprehensive alcohol intake history was obtained to assess lifetime use in terms of quantity and pattern during follow-up. Patients were classified as mild (< 60 g/day) or heavy (≥ 60 g/day) drinkers. Non-drinkers were defined as those drinking < 10 g of alcohol/day.
Patients were re-examined at 6-month intervals. A clinical evaluation of symptoms, toxic habits, and physical evaluation was performed at each study visit. Additionally, anthropometry and blood test for nutritional evaluation and abdominal ultrasound were performed annually. Morphological evaluation by EUS was performed every second year. Patients underwent other procedures during follow-up (e.g. computed tomography scan, magnetic resonance imaging/magnetic resonance pancreatography after intravenous secretin, and/or pancreatic function test) when clinically indicated.
All clinical information for every patient, including data obtained for the study protocol, is available at a central electronic medical record (EMR), which is shared by all the hospitals and health centers around our geographic region in the northwest of Spain. Any event or newly developed comorbidity is registered at that EMR. Among them, the occurrence of any CV event was also prospectively recorded.
Diagnosis of pancreatic exocrine insufficiency in patients with chronic pancreatitis. Pancreatic exocrine insufficiency was defined as the presence of maldigestion as evaluated by the 13 C-MTG breath test (total cumulative recovery rate at 6 h of < 29%). 28 The 13 C-MTG was not mandatory for PEI diagnosis in patients with symptoms suggestive of maldigestion (e.g. steatorrhea, weight loss, flatulence, and abdominal crampy pain) and an otherwise unexplained abnormal nutritional evaluation, 29 who additionally showed an adequate response to oral PERT (improved nutritional status and symptom relief).
Definition of cardiovascular event. A CV event was defined as any hospitalization due to myocardial infarction or stroke (major adverse cardiovascular event [MACE]), arterial revascularization procedures, or peripheral arterial disease (PAD). PAD was diagnosed by CV surgeons in patients with new onset symptoms compatible with PAD, based on abnormal arterial examination and ankle-brachial index (ABI). To calculate the ABI, systolic blood pressure was measured in both arms (brachial arteries) and both ankles (posterior tibial arteries). Left and right ABI measurements were obtained by dividing the systolic occlusion pressure in the ankle by the highest arm pressure. PAD was defined as an ABI < 0.90 in either leg. We considered an event to be incidental if it occurred in a patient with no previous diagnosis of CV events; only one event counted for patients who had more than one event of the same nature.
Ethics approval. The study was approved by the Ethics Committee of Galicia, Spain, and conducted in accordance with the Declaration of Helsinki and its amendments and Good Clinical Practice guidelines. All patients gave their informed consent prior to their inclusion in the study.
Statistical analysis. Data are shown as percentages, mean, median, standard deviation, 95% confidence intervals (CIs), or range as appropriate. Qualitative data were analyzed by the chisquare test and the Fisher's exact test as appropriate. Quantitative data were analyzed by paired or unpaired Student's t-test or Mann-Whitney U-test, as appropriate. A P value of < 0.05 was considered statistically significant. Baseline characteristics that could have an influence on CV risk, such as gender, age (categorized by quartile), body mass index, alcohol and tobacco consumption (dichotomized as "ever" or "never"), hypercholesterolemia, arterial hypertension, DM, and PEI, were studied as independent variables using a logistic regression model, expressed as odds ratio (OR) with 95% CI, and Cox proportional hazards regression model and expressed as hazard ratio (HR) with 95% CI. Population attributable risk was calculated by using adjusted ORs from the final multivariable logistic regression model for each variable that was significantly associated with an increased risk of CV events. CV event-free survival curves were plotted according to Kaplan-Meier, using log-rank Mantel-Cox tests. Statistical analyses were conducted using STATA 13 (StataCorp LP, Texas).
Results
Study population. In total, 455 patients were included in the EPNAT-CP study, and 430 patients completed the follow up for a mean of 8.6 ± 4.6 years from diagnosis. Patient characteristics at baseline are shown in Table 1 . Almost 80% of the patients were male with a mean age of 47.8 years. Approximately two-thirds of patients (67.4%) had a toxic CP etiology. Over 60% of patients consumed tobacco and/or alcohol at baseline (62.6% and 63.4%, respectively). The median number of cigarettes smoked per day was 20 (range 3-60) and the median quantity of alcohol consumed was 80 g/day (range 20-200). At baseline, 19.4% of patients had arterial hypertension and 43.3% hypercholesterolemia; 29.5% of patients had DM and 29.3% PEI (17.2% of patients had both PEI and DM). In total, 58.3% of patients had neither DM nor PEI.
Age and gender distributions between the patients with or without PEI were similar. Significant differences were observed in the etiology of CP between patients with and without PEI, with a greater proportion of those with PEI having a toxic or genetic etiology (74.6% vs 64.5% [P = 0.041] and 9.5% vs 2.6% [P = 0.002], respectively) and fewer having an idiopathic etiology (12.7% vs 26.3%; P = 0.002). Patients with PEI received a median dose of PERT of 150 000 lipase units per day (range 30 000-350 000). There was no significant difference in tobacco or alcohol consumption between the patients with or without PEI or in the proportion of patients with hypertension or hypercholesterolemia; however, as expected, a greater proportion of patients with PEI had DM (58.7% vs 17.4%; P < 0.001).
Incidence of cardiovascular events. Cardiovascular events occurred in 45 patients (10.5%) giving an incidence of 1.26 per 100 patients/year. Of the 45 patients, 21 (46.7%) had a MACE and 27 (60.0%) had a peripheral artery disease. CV events Table 2 . A significantly greater proportion of the patients who had a CV event were older at CP diagnosis (P = 0.001), male (P < 0.001), and had a toxic etiology of the disease (P < 0.001). Significantly more patients with a CV event consumed tobacco (P < 0.001) or alcohol (P = 0.019). More than twice as many patients who had a CV event had arterial hypertension or DM compared with those without a CV event (40.0% vs 17.0%, P < 0.001; 57.8% vs 26.2%, P < 0.001, respectively). Among the 45 patients who had a CV event, 29 (64.4%) had PEI. Patients with PEI were significantly younger when the CV events occurred (mean 50.9 vs 58.9 years of age; P = 0.019), and a significantly greater proportion had DM (72.4% vs 31.3%; P = 0.012).
Analysis of factors associated with cardiovascular events. A logistic regression model was used to detect factors significantly and independently associated with CV events in patients with CP (Table 3) . Univariate analyses revealed highly significant relationships between CV events and PEI (OR 3.97, 95% CI 1.51-10.42; P = 0.005), coexistence of PEI and DM (OR 8.64, 95% CI 3.93-19.01; P = 0.000), and male gender (OR 13.23, 95% CI 1.8-97.39; P = 0.011). Highly significant relationships were also revealed between CV events and known CV risk factors, including smoking (OR 4.38, 95% CI 1.81-10.6; P = 0.001), alcohol consumption (OR 2.26, 95% CI 1.09-4.7; P = 0.029), arterial hypertension (OR 3.25, 95% CI 1.63-6.47; P < 0.001), and age at diagnosis of CP > 58 years old (OR 4.49, 95% CI 1.44-14.01; P = 0.01). However, no significant relationship was detected between CV events and hypercholesterolemia (OR 0.90, 95% CI 0.47-1.69; P = 0.734) or diabetes in the absence of PEI (OR 2.27, 95% CI 0.76-6.84; P = 0.144). In multivariate analysis, significant associations were revealed between CV events and smoking (OR 2.91, 95% CI 1.10-7.97; P = 0.037), PEI (OR 4.96, 95% CI 1.68-14.65; P = 0.004), coexistence of PEI and DM (OR 6.54, 95%CI 2.71-15.77; P = 0.000) and arterial hypertension (OR 3.40, 95%CI 1.50-7.21; P = 0.003). The proportion of CV events that could be attributed to the presence of PEI (no DM) and PEI associated with DM was estimated to be 13.21% and 38.59%, respectively (Table 3) .
Levels of nutritional markers such as prealbumin, retinolbinding protein, albumin, and magnesium were significantly lower in patients who experienced a CV event than in patients who did not (Table 4) . Plasma HbA1C was significantly higher in patients who experienced a CV event than in those who did not (7.53% ± 1.93% and 6.44% ± 1.65%, respectively; P = 0.005).
Cardiovascular event-free survival in patients with chronic pancreatitis. After controlling for potentially confounding factors, the multivariable Cox proportional hazard regression model revealed significant relationships between CV events and PEI without the coexistence of DM (HR 3.13, 95% CI 1.15-8.56; P = 0.026), coexistence of PEI and DM (HR 3.46, 95% CI 1.47-8.10; P = 0.004), smoking (HR 2.63, 95% CI 1.02-6.72; P = 0.043), arterial hypertension (HR 2.89, 95% CI 1.40-5.97; P = 0.004), and age at the diagnosis of CP (HR 1.04, 95% CI 1.01-1.07; P = 0.007). Multivariate CV event-free survival analysis showed that survival in patients with PEI with and without coexistence of DM was significantly reduced compared with patients without PEI and DM (log-rank test P < 0.001; Fig. 1 ).
Discussion
This prospective, longitudinal study evaluated the risk of CV events and the impact of PEI in a well-phenotyped cohort of patients with CP. All patients were under long-term follow-up after participation in a large-scale study on the EPNAT-CP. The study demonstrated for the first time that PEI is an independent factor significantly associated with an increased risk of CV events in patients with CP; the incidence rate ratio for CV events was 3.67 (95% CI 1.92-7.24; P < 0.001) for patients with and without PEI. Furthermore, CV event-free survival in patients with PEI with and without DM was significantly reduced compared with patients without PEI and DM.
Several risk factors for CV disease are already well-established, including smoking, arterial hypertension, dyslipidemia, obesity, and DM. 30 Patients with CP frequently exhibit a number of these risk factors as shown in the present study: 62.5% of patients consumed tobacco and/or alcohol, 19.4% had arterial hypertension, 43.3% hypercholesterolemia, and 29.5% had DM. Previous studies have shown that CP is associated with an increased risk of CV disease. A prospective study found CV lesions in 18 of 54 patients with proven CP (33.3%) compared with 5/54 (9.3%) of control subjects (P < 0.01). These lesions consisted of electrocardiographic changes indicating the presence of coronary heart disease in eight of the CP patients versus three controls and of peripheral vascular symptoms and signs indicating obliterate arterial lesions of the lower extremities in 12 CP patients versus two controls. 10 Other recent cohort studies conducted in Taiwan have reported that patients with CP have increased risk of cerebrovascular disease, 31 acute coronary syndrome, 11 and deep vein thrombosis and pulmonary thromboembolism. 32 Malnutrition secondary to different diseases is a well-known cause of CV disease and events. [13] [14] [15] [16] [17] Several studies have shown nutritional deficiencies in patients with CP. 8, [33] [34] [35] Maldigestion, as a consequence of PEI, results in malabsorption of fat, protein, and fat-soluble vitamins. PEI is therefore a major cause of malnutrition in CP, and thus, it may increase the risk of CV events. Vitamin D deficiencies have been associated with arterial hypertension, obesity, DM, and metabolic syndrome, as well as with CV events such as stroke and congestive heart failure. 12, 16 Furthermore, such deficiencies have been associated with 17 while protein-energy malnutrition has been found to increase the risk of mortality from CV disease in patients with end-stage renal disease. 36 Our findings in patients with CP are in agreement with these previously reported data, and patients with CV events had significantly lower levels of prealbumin, retinol-binding protein, albumin, and magnesium compared with those who did not.
It is notable that PEI was associated with an increased CV risk in our study despite PERT at a median daily dose of 150 000 Ph.U. Recent guidelines from the UK and Spain have suggested that higher starting doses of oral pancreatic enzymes (50 000-75 000 Ph.U./ meal) should be used. 37, 38 Other potential explanation is that PERT could be prescribed too late to reverse the effect of PEI on the CV risk. In fact, PERT is usually given once PEI is clinically evident (overt steatorrhea, weight loss, and/or nutritional deficiencies). Future studies should answer the question of to what extent early prescription of PERT can prevent nutritional deficiencies in CP. In addition, further studies are required to understand if optimization of PERT can further improve digestion and nutritional status in patients with PEI and to what extent such strategies can reduce the incidence and prevalence of potential PEI-related complications, such as CV events, in patients with CP.
Pancreatic exocrine and endocrine insufficiency is a frequent complication developing along the natural history of CP. In the current study, more than 40% of our patients had exocrine and/or endocrine pancreatic insufficiency. Our data support that both PEI and DM are associated with the CV risk in patients with CP. The presence of PEI was significantly associated with increased risk of CV events in patients without DM, and the presence of DM increased the risk of CV events in patients with PEI. In addition, plasma HbA1c levels were significantly higher in patients who had a CV event.
Other comorbid conditions classically associated with CV risk, such as hypercholesterolemia, showed no significant association with an increased CV risk in this study. This can be explained by the high proportion of patients receiving lipid-lowering treatment at the time of inclusion.
The large, well-defined patient population and their relative long-term follow-up were a key strength of this study. Accurate methods were used for the diagnosis of both CP and PEI. This was a single-center study, so there was a limited variability in terms of standard of care. A regional EMR, shared by all general practitioners, emergency units, and hospitals, prospectively recorded any health issue, including any CV event, which ensured comprehensive data capture.
Although the cohort of our study is robust in terms of size (430 patients with CP) and time of follow-up (8.6 years as a mean), the number of new CV events recorded prospectively over the study period is relatively small, which reflects the true incidence of CV events in clinical practice. However, because of this, the CIs reported are quite wide, which can be considered as a limitation of the study.
Conclusion
This study demonstrates for the first time that PEI is an independent factor significantly associated with an increased risk of CV events in patients with CP. Together with other known major CV risk factors, such as age, DM, smoking, hyperlipidemia, and arterial hypertension, PEI increases the risk of CV-related morbidity. PEI, as a cause of nutritional deficiencies, exacerbates the health burden of patients with CP. To what extent early and optimal PERT, together with treatment of other risk factors, may reduce the CV risk in patients with CP deserves further investigation.
